Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CMA1 | P23946 | 1/20 | 0.66 |
| ▸ | GSK3A | P49840 | 2/20 | 0.62 |
| ▸ | GSK3B | P49841 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | APAF1 | O14727 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3384174 | 0.77 | GSK3A (1.00) | CMA1GSK3AGSK3BALDH1A1MEN1 | |
| SCHEMBL19585594 | 0.76 | CYP19A1 (0.63) | CMA1GSK3AGSK3BALDH1A1MEN1 | |
| SCHEMBL1773322 | 0.76 | CMA1 (0.60) | CMA1GSK3AGSK3BALDH1A1MEN1 | |
| SCHEMBL8331785 | 0.75 | CMA1 (0.70) | CMA1GSK3AGSK3BALDH1A1MEN1 | |
| SCHEMBL41389 | 0.75 | CMA1 (0.70) | CMA1GSK3AGSK3BALDH1A1MEN1 | |
| SCHEMBL2643216 | 0.75 | CMA1 (0.70) | CMA1GSK3AGSK3BALDH1A1MEN1 | |
| SCHEMBL10341833 | 0.75 | CMA1 (0.64) | CMA1GSK3AGSK3BALDH1A1MEN1 | |
| SCHEMBL40778 | 0.72 | CMA1 (0.66) | CMA1GSK3AGSK3BALDH1A1MEN1 | |
| SCHEMBL30296449 | 0.72 | CASP3 (0.88) | CMA1MEN1KMT2AKDM4ECASP3 | |
| SCHEMBL45154 | 0.72 | CASP3 (0.88) | CMA1MEN1KMT2AKDM4ECASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637516-B2 | Compounds and compositions as TRK inhibitors | IRM LLC (BM) | 2014-01-28 | — | — | US | disclosed |
| US-8637516-B2 | Compounds and compositions as TRK inhibitors | IRM LLC (BM) | 2014-01-28 | — | — | US | disclosed |
| EP-2614062-A1 | IMIDAZO [1, 2]PYRIDAZIN COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2013-07-17 | — | — | EP | disclosed |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | disclosed |
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | US | disclosed |
| WO-2012034091-A1 | IMIDAZO [1, 2] PYRIDAZIN COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012034091-A1 | IMIDAZO [1, 2] PYRIDAZIN COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065184-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | TNK2, CNKSR1, BMP2K | CMA1 4346/4885GSK3A 191/4885GSK3B 149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.